Layn(SZ:002166) Xin Lang Cai Jing·2025-12-25 01:57Core Viewpoint - Rhine Biotech's stock price has shown significant fluctuations, with a recent decline despite an overall increase in stock value for the year, indicating potential volatility in investor sentiment and market dynamics [1][2]. Group 1: Stock Performance - Rhine Biotech's stock price decreased by 2.09% to 9.37 CNY per share, with a trading volume of 249 million CNY and a turnover rate of 3.42%, resulting in a total market capitalization of 6.949 billion CNY [1]. - Year-to-date, Rhine Biotech's stock has increased by 27.10%, with a 7.58% rise over the last five trading days, a 12.48% increase over the last 20 days, and an 18.16% increase over the last 60 days [2]. Group 2: Company Overview - Rhine Biotech, established on November 28, 2000, and listed on September 13, 2007, is located in Guilin, Guangxi, and primarily engages in the production and operation of natural health products, focusing on the extraction of functional plant components [2]. - The company's revenue composition is heavily weighted towards plant extraction products, accounting for 98.05%, while other business products contribute 1.95% [2]. - Rhine Biotech is classified under the basic chemical industry, specifically in chemical products related to food and feed additives, and is associated with various concept sectors including specialized and innovative enterprises, beer, margin trading, small-cap stocks, and sugar substitute concepts [2]. Group 3: Financial Performance - For the period from January to September 2025, Rhine Biotech reported a revenue of 1.272 billion CNY, reflecting a year-on-year growth of 8.73%, while the net profit attributable to shareholders decreased by 30.73% to 70.395 million CNY [2]. - The company has distributed a total of 431 million CNY in dividends since its A-share listing, with 294 million CNY distributed over the past three years [3]. Group 4: Shareholder Information - As of September 30, Rhine Biotech had 46,000 shareholders, a decrease of 1.66% from the previous period, with an average of 16,011 circulating shares per shareholder, which is an increase of 31.16% [2].